Ideaya Biosciences received FDA clearance to begin a Phase I trial of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 linked to a TOP1 payload, for solid tumors. The investigational candidate combines two tumor antigen targets to enhance tumor selectivity and payload delivery. The IND clearance enables first‑in‑human dosing and positions Ideaya to test a dual‑target ADC approach designed to broaden ADC activity in heterogeneous solid tumors.